Last reviewed · How we verify
Signal Switch Receptor Modified TIL — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Signal Switch Receptor Modified TIL (Signal Switch Receptor Modified TIL) — Shanghai Juncell Therapeutics.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Signal Switch Receptor Modified TIL TARGET | Signal Switch Receptor Modified TIL | Shanghai Juncell Therapeutics | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Signal Switch Receptor Modified TIL CI watch — RSS
- Signal Switch Receptor Modified TIL CI watch — Atom
- Signal Switch Receptor Modified TIL CI watch — JSON
- Signal Switch Receptor Modified TIL alone — RSS
Cite this brief
Drug Landscape (2026). Signal Switch Receptor Modified TIL — Competitive Intelligence Brief. https://druglandscape.com/ci/signal-switch-receptor-modified-til. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab